TY - JOUR
TI - Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use.
AU - van Straalen, Joeri W.
AU - Krol, Roline M.
AU - Giancane, Gabriella
AU - Panaviene, Violeta
AU - Ailioaie, Laura Marinela
AU - Doležalová, Pavla
AU - Cattalini, Marco
AU - Susic, Gordana
AU - Sztajnbok, Flavio
AU - Maritsi, Despoina
AU - Constantin, Tamas
AU - Sawhney, Sujata
AU - Rygg, Marite
AU - Oliveira, Sheila Knupp
AU - Nordal, Ellen Berit
AU - Saad-Magalhaes, Claudia
AU - Rubio-Perez, Nadina
AU - Jelusic, Marija
AU - de Roock, Sytze
AU - Wulffraat, Nico M.
AU - Ruperto, Nicolino
AU - Swart, Joost F.
JO - Rheumatology (Oxford, England)
PY - 2021
VL - null
TODO - null
SP - keab678
PB - 
SN - null
TODO - 10.1093/rheumatology/keab678
TODO - inflammatory bowel disease, enthesitis-related arthritis, etanercept, juvenile idiopathic arthritis
TODO - OBJECTIVES: To describe risk factors for inflammatory bowel disease (IBD) development in a cohort of children with juvenile idiopathic arthritis (JIA).  METHODS: JIA patients who developed IBD were identified from the international  Pharmachild register. Characteristics were compared between IBD and non-IBD patients  and predictors of IBD were determined using multivariable logistic regression  analysis. Incidence rates of IBD events on different disease-modifying  anti-rheumatic drugs (DMARDs) were calculated, differences between therapies were  expressed as relative risks (RR). RESULTS: Out of 8,942 patients, 48 (0.05\%)  developed IBD. These were more often male (47.9\% vs 32.0\%) and HLA-B27 positive  (38.2\% vs 21.0\%) and older at JIA onset (median 8.94 vs 5.33 years) than patients  without IBD development. They also had more often a family history of autoimmune  disease (42.6\% vs 24.4\%) and enthesitis-related arthritis (ERA) (39.6\% vs 10.8\%).  The strongest predictors of IBD on multivariable analysis were ERA (OR: 3.68, 95\%  CI: 1.41-9.40) and a family history of autoimmune disease (OR: 2.27, 95\% CI:  1.12-4.54). Compared with methotrexate monotherapy, the incidence of IBD on  etanercept monotherapy (RR: 7.69, 95\% CI: 1.99-29.74), etanercept with methotrexate  (RR: 5.70, 95\% CI: 1.42-22.77) and infliximab (RR: 7.61, 95\% CI: 1.27-45.57) therapy  was significantly higher. Incidence on adalimumab was not significantly different  (RR: 1.45, 95\% CI: 0.15-13.89). CONCLUSION: IBD in JIA was associated with ERA and a  family history of autoimmune disease. An increased IBD incidence was observed for  etanercept therapy regardless of concomitant methotrexate use.
ER -